nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-3325FFDE·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.1 Basic medicine·Subfield: Physiology·Basis: Full text·Type: Laboratory experiment

Meprin-β levels are increased in the brain and the cerebrospinal fluid of Alzheimer's disease patients.

Escamilla et al.Escamilla, Avilés-Granados, Márquez-Marco et al.·2026·Alzheimer's research & therapy·10.1186/s13195-026-02092-7 ↗

Primary claim

Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen.

Tentative · age-imbalanced groups, indirect band assignment, uncorrected comparisons, and inconsistent dispersion reporting limit the late-Braak association
In brief

Meprin-β characterization across brain, CSF, and model systems offers an incremental Alzheimer's signal, but uncontrolled age confounding limits the central association.

ReliabilityConcerns4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

The aim of this study is to assess the levels of meprin-β, an alternative β-secretase in the brain and cerebrospinal fluid of subjects suffering Alzheimer's disease. The full-length zymogen and the active species of meprin-β were characterized by immunoblotting and immunoprecipitation using ectodomain N-terminal and C-terminal antibodies. We examined meprin-β changes in extracts from Alzheimer's frontal cortex (n = 13, Braak stages I-II; n = 12, Braak stages III-IV; n = 12, Braak stages V-VI) compared with controls (n = 14), as well as in cerebrospinal fluid samples from Alzheimer's patients (n = 15) or non-Alzheimer's controls (n = 15). Cerebrospinal fluid meprin-β levels were also determined in 19-month old TgF344-AD and wild-type rats. Brain and cerebrospinal fluid from a Mep1b-null mouse served to characterize the specificity of the immunoreactive bands for meprin-β. Human induced pluripotent stem cell (iPSC)-derived neuronal cultures were treated with 2 μM Aβ42 for 24 h. We found that meprin-β is present in human brain extracts and cerebrospinal fluid as several distinct species, attributed to the zymogen and the mature species. These species were absent in brain and cerebrospinal fluid from a Mep1b-null mouse. No fragments of meprin-β were detected in brain extract, either in cerebrospinal fluid. Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen. The MEP1-B mRNA levels are increased in Braaks III-IV and V-VI compared with controls. The meprin-β species are increased in human neuronal cultures treated with Aβ42. Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats. Our data support a role of meprin-β in Alzheimer's pathology.

Key Claims

Primary finding · Tentative

Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

age-imbalanced groups, indirect band assignment, uncorrected comparisons, and inconsistent dispersion reporting limit the late-Braak association

Abstract; Results, Fig. 3B
Quote verified
Secondary · Tentative

Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats.

small exploratory comparisons and incompatible SEM–p-value reporting materially limit confidence in the CSF result

Abstract; Results, Figs. 5–6
Quote verified
Secondary · Tentative

The meprin-β species are increased in human neuronal cultures treated with Aβ42.

one donor line, supraphysiological treatment, and unreported independent differentiation counts constrain the observed response

Abstract; Results, Fig. 4D
Quote verified
Secondary · Tentative

Our data support a role of meprin-β in Alzheimer's pathology.

cross-sectional associations and one acute cell treatment do not identify a pathological role

Abstract; Discussion, Summary
Quote verified
Secondary · Supported

The MEP1-B mRNA levels are increased in Braaks III-IV and V-VI compared with controls.

adjacent frontal-cortex tissue showed stage-specific transcript differences, though the exploratory comparisons were not multiplicity-adjusted

Abstract; Results, Fig. 3C
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Knockout-supported antibody specificity checks

Brain and CSF from Mep1b-null mice were used alongside N-terminal and C-terminal antibodies to assess which immunoreactive bands were attributable to meprin-β.

↳ Results, Figs. 1A and 2A

#contribution

Multiple systems address one question

The study examines human brain, human CSF, iPSC-derived neurons, TgF344-AD rat CSF, and knockout mouse material, providing convergent descriptive observations across matrices and species.

↳ Methods; Results, Figs. 1–6

#positioning

Key assay limitations are acknowledged

The Discussion states that molecular mass does not directly prove maturation, brain and CSF samples were unpaired, activity was not measured, and independent replication is needed.

↳ Discussion, limitations paragraphs

Limitations

#methodological rigour

Age confounding affects brain comparison

Controls averaged 55 years, whereas Braak V–VI cases averaged 75 years, and no matched or between-group age-adjusted analysis was reported. Within-group correlations do not isolate disease status from this imbalance.

↳ Methods, Human Brain and CSF Samples; Results, Fig. 3B

#reporting

Quantitative reporting does not cohere

Values are declared to be means ± SEM, yet examples such as CSF 171 ± 108% with p=0.041 appear incompatible with that convention. Effect magnitudes are also described inconsistently as relative levels or increases.

↳ Methods, Statistical Analysis; Results, Figs. 3B–6B

#methodological rigour

Species assignment remains indirect

The mature-versus-zymogen interpretation rests principally on an approximately 10 kDa mobility difference without a pro-domain or processed-N-terminus antibody, and enzymatic activity was not measured.

↳ Discussion, meprin-β species interpretation and limitations paragraphs

Does this match your read? Add your assessment ↓

Nabu Commentary

The study's main contribution is the combination of Braak-stratified brain measurements, human and rat CSF observations, and knockout-supported band characterization. The strongest methodological concern is the approximately 20-year age difference between controls and late-Braak cases without a matched or adjusted analysis, which limits attribution of the brain association to Alzheimer's pathology. Confidence is further reduced by unclear independent replication in the single-donor iPSC arm and by statistical and reagent-reporting inconsistencies. The Discussion acknowledges important uncertainty about molecular-species assignment and absent activity measurements, but it does not integrate the age imbalance into its limitations or final interpretation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.8±0.2

Contribution
3.1

The study extends prior brain findings through Braak-stage stratification, CSF analysis, and knockout-supported band characterization. The advance remains incremental and descriptive rather than mechanistic.

Introduction, final two paragraphs; Results, Figs. 1–6

“We report an increase in the mature species of meprin-β in brain and CSF of AD patients”

Methodological Rigour
2.5

Knockout tissue, multiple antibodies, immunoprecipitation, internal blot controls, and total-protein normalization support the assays. The central brain comparison is age-imbalanced without adjustment, while blinding and independent iPSC differentiation counts are unreported.

Methods, Human Brain and CSF Samples; Methods, Western Blot; Results, Figs. 1–5

“Non-demented, control subjects consisted of 14 cases... 55 ± 11 years”

Reporting
3.2

The progression from band characterization to human and model-system comparisons is readily followable. Reagent and figure-caption discrepancies, inconsistent effect reporting, and language claiming a pathological role reduce interpretive precision.

Results, Figs. 1C and 2C; Discussion, Summary

“provide sufficient evidence to support a role of meprin-β in AD pathology”

Positioning
2.8

The paper discusses alternative β-secretases, prior meprin-β findings, band-assignment uncertainty, unpaired brain and CSF samples, and absent activity measurements. It does not incorporate the marked age imbalance into its limitations analysis despite its relevance to the central late-Braak comparison.

Introduction; Methods, Human Brain and CSF Samples; Discussion, limitations paragraphs

“the present finding should be considered conservatively”

Reliability

Concerns4 of 4 checks


Results checkConcern
  • Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats: "When we compared the levels of meprin-β in control and AD cases, we obtained elevated levels of the mature meprin-β in the CSF of patients with AD (171 ± 108%; p = 0.041), while the level of the zymogen remained unaltered (Fig. 5B)." (Results, Meprin-β is increased in the CSF of AD patients, Fig. 5B) vs "The results are presented as the means ± standard error of the mean (SEM), and all the analyses were performed using GraphPad Prism (version 7; GraphPad Software, Inc)." (Methods, Statistical analysis). With 15 subjects per group, control mean 100% under the stated normalization, and AD SEM 108%, the stated Student’s t-test gives |t| = 71/√(108² + SEM_control²) ≤ 0.6574 with 28 degrees of freedom, so its two-sided p-value is at least approximately 0.516 rather than 0.041. → Loses significance
  • The meprin-β species are increased in human neuronal cultures treated with Aβ42: "We demonstrated that Aβ42 can trigger an increase in the levels of the meprin-β attributed to the mature species (69 ± 15%; p = 0.001), as well for the zymogen species (50 ± 20%; p = 0.032), compared with controls (Fig. 4C)." (Results, iPSC-derived neurons treated with Aβ42) vs "D Quantification of the levels of meprin-β immunoreactive bands attributed to mature and zymogen levels was normalized to loading control α-tubulin and expressed as percentages with respect to controls." (Fig. 4D caption). The reported 69% and 50% denote increases in the Results wording but levels below the 100% control baseline under the caption’s convention, and the supplied text does not establish which convention describes the measurements. → Effect on result unclear
  • Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats: "CSF meprin-β levels were higher in TgF344-AD animals than in wild-types (63 ± 25%; p = 0.026, Fig. 6B)." (Results, TgF344-AD rat CSF) vs "B Data are expressed as percentages with respect to wild-type control rats." (Fig. 6B caption). A level of 63% of wild-type controls would be 37% lower, whereas a 63% increase would be a level of 163%, and the Results and caption do not establish which quantity was measured. → Effect on result unclear
Reporting and transparencyNoted

The immunoprecipitation antibody identifier conflicts between Methods and Results, and the CSF characterization caption identifies brain homogenate as its material; neither issue establishes a corrected quantitative result.

Ethics approval: declared · Preregistration: not stated · Data availability: not stated

Reference IntegrityClean

48 references in manuscript 48 of 48 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on observational quantification in post-mortem human brain tissue, with no intervention or functional demonstration shown working.

From the paper
“the determination of meprin-β in biological fluids could serve to monitor the disease.”

The paper names a possible real-world use of its findings, measuring meprin-β in fluids as a disease-monitoring biomarker, but does not say who would act on it.

Pathway

Neurology researchers and drug developers could pursue meprin-β as an Alzheimer's biomarker in CSF and as a target informing β-secretase inhibitor design.

Barrier

Small cohorts, no enzymatic activity measurement, and acknowledged caveats in species identification mean independent replication in larger cohorts is required first.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →